Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2024
Q3
Sell
-6,000
Closed -$77.5K 952
2024
Q2
$76K Buy
+6,000
New +$60.4K ﹤0.01% 774
2022
Q4
Sell
-3,800
Closed -$67.1K 1058
2022
Q3
$69K Sell
3,800
-12,524
-77% -$543K ﹤0.01% 855
2022
Q2
$840K Buy
+16,324
New +$846K 0.03% 464
2022
Q1
Sell
-1,178
Closed -$105K 1266
2021
Q4
$169K Sell
1,178
-6,542
-85% -$1.12M 0.01% 933
2021
Q3
$1.6M Buy
+7,720
New +$1.7M 0.07% 297
2021
Q2
Sell
-2,664
Closed -$488K 1140
2021
Q1
$483K Sell
2,664
-11,836
-82% -$2.36M 0.02% 594
2020
Q4
$1.62M Buy
14,500
+5,579
+63% +$593K 0.06% 228
2020
Q3
$967K Buy
8,921
+7,921
+792% +$965K 0.05% 301
2020
Q2
$83K Buy
+1,000
New +$38.2K ﹤0.01% 564

Other funds holding NVAX

CSS LLC's NVAX Position: Q3 2024 in Review

CSS LLC sold out of Novavax (NVAX) in Q3 2024, closing a stake of 6,000 shares — an estimated $77.5K sold.

CSS LLC first reported a position in NVAX in Q2 2020 and held it in 9 quarters. The position peaked at $1.62M in Q4 2020. 238 funds tracked by Wall St. Rank hold NVAX as of Q3 2024.

  • CSS LLC reported no remaining Novavax position as of Q3 2024 after selling out during the quarter.
  • CSS LLC sold 6,000 Novavax shares in Q3 2024, an estimated $77.5K.
  • CSS LLC first reported a position in Novavax in Q2 2020 and held it in 9 quarters.
  • CSS LLC's Novavax position peaked at $1.62M in Q4 2020.
  • 238 funds tracked by Wall St. Rank held Novavax as of Q3 2024.

Based on CSS LLC's 13F filing for Q3 2024, filed 14 Nov 2024.